| 1. |
The US Department of Health and Human Services, along with experts from the AMA, the AAP and the CDC,*is urging the most vulnerable individuals in the US to seek immunisation against influenza this season, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Recommendation classification system proposed by AAP |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Topical mupirocin and fusidic acid are the best options for the treatment of limited impetigo, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Insulin glargine superior long-term therapy for type 2 DM in Europe |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 5-6
L Everitt,
Preview
|
|
摘要:
The socioeconomic burden of type 2 diabetes mellitus (DM) is onerous, due to its high prevalence and mortality, and the acute and chronic complications associated with the condition. In order to assess both the clinical and economic benefits of new therapies for type 2 DM, it is essential to establish the cost of the disease. At the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Munich, Germany; September 2004], researchers from Switzerland established that insulin glargine is a cost-effective alternative to NPH insulin [insulin suspension isophane] in patients with type 2 DM in that country,1while investigators from Spain and the US reached the same conclusion regarding these treatments among type 2 diabetic patients in Spain.2
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Patients with migraine are still not receiving optimal care, despite the availability of effective, migraine-specific medicines, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Dexamethasone of economic benefit among children with mild croup |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Fenoldopam may prevent renal failure after liver transplantation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Insulin glulisine offers flexible control in diabetes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 9-10
S Sullivan,,
Preview
|
|
摘要:
Insulin glulisine [Apidra] provides effective glycaemic control at mealtimes for patients with type 1 diabetes mellitus (DM) and type 2 DM, according to studies presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Munich, Germany; September 2004]. Patients with type 2 DM receiving insulin glulisine had significantly lower HbA1clevels and improved postprandial control compared with regular human insulin recipients. A second study involving patients with type 1 DM showed that insulin glulisine effectively lowered blood glucose levels when administered preprandially and up to 20 minutes postprandially.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G*(IVIG), |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Epratuzumab has promising activity in aggressive NHL |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1457,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
